Genprex (NASDAQ:GNPX) Stock Skyrockets 40% on Lung Cancer Gene Therapy Breakthrough
Genprex shares surged 41% after hours on Oct 14, 2025, to $0.36 following new data on its lead cancer therapy. The stock closed regular trading up 30% at $0.25, with volume spiking to 15 million shares. Market cap reached about $11 million. The company’s REQORSA gene therapy is in Phase 2 trials for lung cancer, with new preclinical data set for release at an upcoming oncology conference.
